Skip to main content

Table 3 Genome-wide association studies of antidepressant treatment response

From: Genome-wide approaches to antidepressant treatment: working towards understanding and predicting response

Sample

GWAS sample size (N)

Microarray used

Primary outcome measure

Response phenotype definition

SNPs reaching suggestive levels of significance (nearest gene)

STAR*D [5]

1,948

Affymetrix 500K/5.0 human SNP arrays

QID-SR

Response: >50% reduction in score

rs6966038 (UBE3C), rs6127921 (BMP7), rs809736 (RORA)

    

Remission: score <5

  

MARS [9]

339 (two replication samples, N=361 and N=831)

Sentrix Human-1 and HumanHap300 BeadChip

HAM-D

Early partial response: >25% reduction in score after 2 weeks of treatment

rs6989467 (CDH17)a, rs1502174 (EPHB1)

    

Response: >50% reduction in score

  
    

Remission: score <10

  

GENDEP [13]

706

Illumina 610 array

MADRS

Percentage change from baseline to week 12

Whole-sample analysis

rs2136093, rs6701608 and rs2136094 (intergenic, on chromosome 1)rs16920624, rs11598854 and rs7081156 (intergenic, on chromosome 10)

     

Escitalopram-specific analysis

rs1126757 (IL11)

     

Nortriptyline-specific analysis

rs2500535 (UST)

     

Gene-by-drug analysis

rs2500535 (UST)

  1. aOnly associated with early partial response. GWAS, genome-wide association study; HAM-D, Hamilton Depression Rating Scale; MADRS, Montgomery-Asberg Depression Rating scale; QID-SR, Quick Inventory of Depressive Symptomatology Self-Report version; SNP, single nucleotide polymorphism.